Top Markets
Coin of the day
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Rangering i aksjer #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Aksjekurs
$0.00162013
Sist synkronisert: 2025-01-03
Markedsverdi
$156.25K
Endring (1 dag)
0.36%
Endring (1 år)
0.00%
Land
SE
Handel Cyxone AB (publ) (CYXO)

Kategori

EPS for Cyxone AB (publ) (CYXO)
EPS per June 2024 TTM: $-0.01
Ifølge de siste økonomiske rapportene og aksjekursen til Cyxone AB (publ) er selskapets nåværende EPS (TTM) $-0.01. Ved slutten av 2022 hadde selskapet en EPS på $-0.04, en nedgang sammenlignet med EPS-en i 2021 som var $-0.08.
EPS-historikk for Cyxone AB (publ) fra 2015 til 2026
EPS ved slutten av hvert år
År EPS Endre
2026 (TTM) $-0.01 -29.00%
2023 $-0.02 -48.34%
2022 $-0.04 -47.71%
2021 $-0.08 -15.59%
2020 $-0.10 13.00%
2019 $-0.08 88.84%
2018 $-0.04 -16.73%
2017 $-0.05 88.11%
2016 $-0.03 2,100.00%
2015 0.00 0.00%
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -122,071.83%
US
$27.74 -195,452.11%
NL
- -
CH
- -
KR
$13.70 -96,579.58%
BE